S-5041-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Tim Kaine (D-VA)
What it does
This bill would direct the Secretary of Health and Human Services, working with the CDC and NIH, to collect and analyze population-level data on chronic pain using existing federal records, medical claims, and surveys. It would establish a public website called the Chronic Pain Information Hub to aggregate federal data, peer-reviewed research, and annual clinical recommendations. The bill also requires conflict-of-interest disclosures from collaborators who receive payments from drug or device manufacturers, mandates a congressional report within two years, and authorizes funding for fiscal years 2026 through 2030.
Who benefits
The approximately 50 million Americans living with chronic pain who may benefit from improved research, better treatment guidelines, and more effective care options. Clinicians and researchers who would gain standardized data definitions and a centralized resource for evidence-based findings. Public health agencies that would have better epidemiological data to guide policy. Non-opioid treatment providers (physical therapists, pain psychologists, integrative medicine practitioners) whose approaches would receive dedicated research attention. Patients with co-occurring conditions such as depression, anxiety, and substance use disorders who may benefit from improved understanding of those links.
Who is hurt
Opioid manufacturers and distributors whose products may face unfavorable comparative effectiveness findings published on the Hub. Federal agencies that would bear implementation and maintenance costs. Collaborators with industry ties who would face new public disclosure requirements, potentially limiting their participation. Taxpayers who would fund the program, though the authorization amount is unspecified. Privacy advocates may raise concerns about the aggregation of deidentified medical claims data, even if individual records are not directly identified.
Supporters argue
Supporters argue that chronic pain affects an estimated 50 million Americans — more than heart disease, cancer, and diabetes combined — yet federal data collection on its prevalence, causes, and treatment effectiveness remains fragmented and inconsistent. They contend that standardized population research and a centralized public hub would enable clinicians and policymakers to identify which treatments work, reduce unnecessary opioid prescribing, and close documented gaps in care for underserved demographic groups. The bill's conflict-of-interest disclosure requirement, they argue, helps ensure that research recommendations are driven by evidence rather than industry influence.
Opponents argue
Opponents argue that the bill authorizes an open-ended appropriation ("such sums as may be necessary") without specifying a funding cap, creating fiscal uncertainty and potential for unchecked spending growth. They contend that the CDC and NIH already conduct substantial chronic pain research, and that creating a new statutory data system and public hub duplicates existing infrastructure rather than filling genuine gaps. Critics may also argue that the bill's emphasis on "non-opioid and opioid sparing" approaches in the data collection framework could embed a policy preference into ostensibly neutral research, potentially skewing findings before data are gathered.